This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Imprimis Pharmaceuticals Inc (IMMY)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -10.12M -7.64M -5.38M -953.94K
Operating Gains/Losses 0.00 0.00 1.20M -60.29K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -22.90K 0.00 0.00 0.00
(Increase) Decrease in Inventories -159.54K 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 345.36K -239.80K 231.44K 144.98K
(Decrease) Increase In Other Current Liabilities 331.52K 320.31K 18.39K -9.24K
(Increase) Decrease In Other Working Capital 0.00 0.00 -100.00K 20.00K
Other Non-Cash Items 2.61M 2.84M 2.18M 521.29K
Net Cash From Continuing Operations -7.06M -4.44M -1.90M -291.16K
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -7.06M -4.44M -1.90M -291.16K
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Acquisitions -636.37K 0.00 0.00 0.00
Purchases of Short-Term Investments -100.17K -50.00K 0.00 0.00
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -910.53K -70.00K -15.49K 0.00
Issuance of Debt 0.00 0.00 450.00K 300.00K
Cash Used for Financing Activities
Issuance of Capital Stock 621.68K 10.05M 11.92M 100.00K
Repayment of Long-Term Debt -10.43K 0.00 0.00 0.00
Repurchase of Capital Stock -13.11K -191.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 -200.00K 0.00
Other Financing Charges, Net 0.00 0.00 -360.14K -254.14K
Net Cash From Financing Activities 598.14K 10.05M 11.81M 145.86K
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents -7.37M 5.54M 9.89M -145.30K

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

IMMY Imprimis Pharmaceuticals Inc

Chart of IMMY

Analysts Ratings for IMMY

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

IMMY Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs